WO2019189992A1

WO2019189992A1 - Composition for preventing, alleviating or treating inflammatory diseases, containing zanthoxylum schinifolium oil as active ingredient

Info

Publication number: WO2019189992A1
Application number: PCT/KR2018/005432
Authority: WO
Inventors: 강승미; 김소리
Original assignee: 경상남도; 전북대학교산학협력단
Priority date: 2018-03-26
Filing date: 2018-05-11
Publication date: 2019-10-03
Also published as: KR102119855B1; KR20190112431A

Abstract

The present invention relates to a composition for preventing, alleviating or treating inflammatory diseases, containing Zanthoxylum schinifolium oil as an active ingredient. Specifically, it has been ascertained that Zanthoxylum schinifolium oil, extracted by an expeller type oil extraction method, has an effect of reducing the expression of inflammatory cytokines and, particularly, among various varieties (early-maturing variety, late-maturing variety and drought-resistant plants), a drought-resistant plant variety has a remarkable anti-inflammatory effect.

Description

Composition for the prevention, improvement or treatment of inflammatory diseases comprising an acid colostrum as an active ingredient

The present invention relates to a composition for preventing, ameliorating or treating an inflammatory disease comprising an acidic colostrum as an active ingredient.

Inflammation refers to the pathological condition of an abscess formed by the invasion of external infectious agents (bacteria, fungi, viruses, various types of allergens). Specifically, when the external bacteria invade specific tissues and proliferate, the white blood cells of the living body recognize this, and actively attack the multiplying external bacteria. The dead sea of white blood cells generated during this process accumulates in the tissues invaded by the bacteria. At the same time, cell destruction of invading bacteria killed by leukocytes is fused into the invaded tissue, forming an abscess. Inflammation of the abscess may be promoted through anti-inflammatory action. Anti-inflammatory action is to use an antibacterial agent to inhibit the growth of invading bacteria or to activate macrophages that feed on the foreign substances accumulated in the abscess to digest the foreign substances. And promotes inflammation, such as promoting the function of the macrophages to excrete.

In general, an inflammatory reaction is a biodefense reaction process for repairing and regenerating damage caused by an invasion that causes organic changes in cells or tissues of the living body, and this reaction process includes local blood vessels, various tissue cells of body fluids and immune cells This works. Normally, the inflammatory response induced by external invading bacteria is a defense system for protecting the living body, whereas abnormally excessive inflammatory response is induced, and various diseases appear. These diseases are called inflammatory diseases. The inflammatory disease is a disease that threatens human life by amplifying and sustaining inflammation of various inflammatory mediators secreted from target cells activated by external stimuli. Inflammatory diseases caused by such inflammation include asthma, chronic obstructive pulmonary disease, allergies, systemic lupus erythematosus, scleroderma, ulcerative colitis, Crohn's disease, atopic dermatitis, psoriasis, anaphylaxis, dermatitis, diabetic retinopathy, retinitis, macular Degeneration, uveitis, conjunctivitis, arthritis, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, osteoporosis, diabetes, diabetic nephropathy, nephritis, nephritis, Sjogren's syndrome, Crohn's disease, autoimmune pancreatitis, periodontal disease, graft-versus-host disease, chronic pelvic inflammation Diseases, endometritis, rhinitis, tonsillitis, otitis media, sore throat, cystitis and chronic prostatitis.

On the other hand, asthma is an important health problem with more than 300 million patients worldwide. In Korea, the burden of chronic disease is the sixth largest disease. The prevalence of asthma is still increasing in many countries. In Korea, asthma is slowing down as the prevalence of rapid prevalence declined, but adult asthma continues to increase, which is why social asthma is a greater social burden in Korea. This suggests the possibility of coming.

Asthma is one of the most common chronic airway diseases, characterized by symptoms such as shortness of breath, wheezing, tightness of the chest, and coughing along with reversible exhalation of airflow. Asthma is a combination of genetic and environmental factors. Environmental factors include house dust mites and pollen-causing agents and colds, smoking, air pollution and yellow dust. Asthma, which is known to be difficult to cure, appears repeatedly and seizure, so ongoing management is an important disease. These asthma vary depending on the season or worsening factors, such as exercise, allergens (antigens) or irritants, weather changes, respiratory viral infections such as cold. Acute asthma exacerbations can be life threatening. Asthma is most often associated with airway hyperresponsiveness to direct or indirect stimuli or chronic inflammation of the airways and has similar clinical manifestations, but is a non-uniform disease with a combination of different pathophysiology. Most medicines reduce the number of remissions and manifestations, and therefore, there is an urgent need to develop treatments for asthma.

Japanese vinegar belongs to Unhyang family, and essential oils extracted from fruits are mainly used for food and medicine. The vinegar contains limonine (Limonene (58%), citronellal (22%), beta-ferrandene (β-Phellandrene (6.4%)), cineol (Cineol, 2.2%), dipentene (Dipentene, 1.2%) and other essential oils. Most of the colostrums are 30 kinds of fatty acids, which are divided into saturated fatty acids and unsaturated fatty acids. Among them, unsaturated fatty acids are composed of monounsaturated fatty acids and polyunsaturated fatty acids. About 38% of the components of acidic oil (moisture 10.5%, crude protein 9%, crude fat 37.8%, crude fiber 14.5%, crude ash 8%, other 20.3%) were linoleic acid (26%) and linolenic acid (26%). Linolenic (29.2%) and most unsaturated fatty acids such as oleic acid (Oleic, 35%), ash content (8%) is higher than sesame (5.3%), walnut (2.3%), ginkgo (1.2%) It contains a lot. In addition, since it is always in a liquid state at room temperature has a functional characteristic that can be used at all times. Especially, the acidic oil contains 45% or more of polyunsaturated fatty acids linoleic acid and linolenic acid, which are carriers of fat-soluble vitamins A, D, E, and K, and are known to play an essential fatty acid role in the body after taking.

As a technique related to acetic acid, Korean Patent Publication No. 2017-0091804 discloses a composition for preventing, ameliorating or treating an allergic disease, and Korean Patent Publication No. 2017-0132394 is isolated from cholinine or pharmaceuticals thereof An anti-tuberculosis pharmaceutical composition containing an acceptable salt thereof and a method for preparing the same are disclosed, but there is no disclosure about a composition for preventing, ameliorating or treating an inflammatory disease including the acidic colostrum of the present invention as an active ingredient.

The present invention is derived from the above requirements, the present invention provides a composition for the prevention, improvement or treatment of inflammatory diseases comprising an acidic colostrum as an active ingredient, the sancho of Xperla milked Hancho variety according to the present invention The present invention was completed by significantly reducing the expression of inflammatory cytokines in milk and confirming a decrease in the number of inflammatory cells in bronchial alveolar lavage, a decrease in airway hyperresponsiveness and morphological changes in lung tissue in an asthma-induced animal model. .

In order to achieve the above object, the present invention provides a health functional food composition for the prevention or improvement of inflammatory diseases containing acid colostrum milked with the Expela method as an active ingredient.

The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases containing acid colostrum milked by the Expela method as an active ingredient.

The present invention also provides a quasi-drug for improving asthma or atopic dermatitis, which contains acid colostrum milked by the Expela method as an active ingredient.

The present invention relates to a composition for preventing, ameliorating or treating an inflammatory disease comprising an acidic colostrum as an active ingredient, wherein the anhydrous colostrum of the Xpella milked Hancho variety according to the present invention significantly reduces the expression of inflammatory cytokines, and asthma. In this induced animal model, bronchoalveolar lavage fluid reduces the number of inflammatory cells and reduces airway hypersensitivity, and has the effect of inducing morphological changes of lung tissue.

Figure 1 shows the change in the expression level of inflammatory cytokines (IL-25) in A549 cells treated with varietal colostrum by varieties and milking methods. (A) is an early species, (B) is an endemic species, and (C) is an herbaceous variety of the herbaceous variety.

Samples

1, 4 and 7 were milked by hydraulic compression, containing 10% shell;

Samples

2, 5, and 8 were milked by hydraulic pressing, without shells;

Samples

3, 6, and 9 were milked with Xpella and did not contain shells.

Figure 2 shows the change in the expression level of inflammatory cytokines (IL-33) in A549 cells treated with varietal colostrum by varieties and milking methods. (A) is an early species, (B) is an endemic species, and (C) is an herbaceous variety of the herbaceous variety.

Samples

1, 4 and 7 were milked by hydraulic compression, containing 10% shell;

Samples

2, 5, and 8 were milked by hydraulic pressing, without shells;

Samples

3, 6, and 9 were milked with Xpella and did not contain shells.

Figure 3 shows the change in the expression level of inflammatory cytokines (IL-5) in A549 cells treated with varietal colostrum by varieties and milking methods. (A) is an early species, (B) is an endemic species, and (C) is an herbaceous variety of the herbaceous variety.

Samples

1, 4 and 7 were milked by hydraulic compression, containing 10% shell;

Samples

2, 5, and 8 were milked by hydraulic pressing, without shells;

Samples

3, 6, and 9 were milked with Xpella and did not contain shells.

Figure 4 shows the change in the expression level of inflammatory cytokines (TSLP; thymic stromal lymphopoietin) in A549 cells treated with varieties and milking method. (A) is an early species, (B) is an endemic species, and (C) is an herbaceous variety of the herbaceous variety.

Samples

1, 4 and 7 were milked by hydraulic compression, containing 10% shell;

Samples

2, 5, and 8 were milked by hydraulic pressing, without shells;

Samples

3, 6, and 9 were milked with Xpella and did not contain shells.

Figure 5 shows the changes in the expression level of inflammatory cytokines (IL-25, IL-33, IL-5, TSLP) in primary tracheal epithelial cells treated with acetic acid of Hancho variety by milking method will be. Sample 7 was milked by hydraulic compression, containing 10% shell; Sample 8 was milked by hydraulic pressing, without shells; Sample 9 was milked with xpella and does not contain shells.

6 shows a protocol for establishing an asthma-induced animal model and confirming the efficacy of colostrum according to the present invention.

Figure 7 is a result of analyzing the inflammatory cells in the bronchial alveolar lavage fluid (BAL fluids) of the asthma-induced animal model to which the acetic acid of the herb varieties according to the present invention.

8 is a Western blot result confirming the expression changes of cytokines (IL-4 and IL-13) in the lung tissue of an asthma-derived animal model to which the herbal herb of the herb varieties according to the present invention was administered.

9 is a result of analyzing the changes in airway hypersensitivity in the asthma-induced animal model to which the administration of the herbal herb of Hancho variety according to the present invention.

10 is a result of morphological analysis of lung tissue of an asthma-induced animal model to which the acetic acid of Hancho variety according to the present invention was administered.

The present invention relates to a nutraceutical composition for the prevention or improvement of inflammatory diseases containing acid colostrum milked by the Expela method as an active ingredient.

The sancho oil is characterized in that the varieties of hancho varieties, and preferably at least one selected from No. 10, No. 5, No. 15 and No. 930, but not limited thereto.

The inflammatory disease is a disease caused by increased cytokine secretion causing an inflammatory response, specifically, asthma, bronchitis, chronic obstructive pulmonary disease, atopic dermatitis, allergy, systemic lupus erythematosus, scleroderma, ulcerative colitis, Crohn Disease, psoriasis, anaphylaxis, dermatitis, diabetic retinopathy, retinitis, macular degeneration, uveitis, conjunctivitis, arthritis, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, osteoporosis, diabetes, diabetic nephropathy, nephritis, nephritis, Sjogren's syndrome, Crohn's disease, Autoimmune pancreatitis, periodontal disease, graft-versus-host disease, chronic pelvic inflammatory disease, endometritis, rhinitis, tonsillitis, otitis media, sore throat, cystitis and chronic prostatitis, more preferably asthma, allergic inflammation or Atopic dermatitis, but not limited to.

The dietary supplement composition of the present invention may be prepared in any one formulation selected from powders, granules, pills, tablets, capsules, candy, syrups and beverages, but is not limited thereto.

When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as it is or used with other foods or food ingredients, and may be appropriately used according to a conventional method. The active ingredient may be appropriately used depending on the purpose of use (prevention or improvement). In general, in the preparation of food or beverages, the nutraceutical composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less based on the raw materials. However, in the case of long-term intake for health purposes, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.

There is no particular limitation on the type of dietary supplement. Examples of foods to which the health functional food composition may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products, including ice cream, various soups, drinks, tea Drinks, alcoholic beverages, vitamin complexes, and the like, and include all health foods in the conventional sense.

In addition, the nutraceutical composition of the present invention may be prepared as a food, in particular a functional food. The functional food of the present invention may include ingredients that are commonly added. Examples include proteins, carbohydrates, fats, nutrients and seasonings. For example, when prepared with a drink, natural carbohydrates or flavors may be included as additional ingredients in addition to the active ingredient. The natural carbohydrates can be monosaccharides (e.g. glucose, fructose, etc.), disaccharides (e.g. maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g. dextrins, cyclodextrins, etc.) or sugar alcohols (e.g. , Xylitol, sorbitol, erythritol and the like). The flavourant may be a natural flavourant (eg, taumartin, stevia extract, etc.) and a synthetic flavourant (eg, saccharin, aspartame, etc.).

Various nutritional supplements, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonic acid The carbonation agent etc. which are used for a drink can be contained further. Although the ratio of the above-mentioned ingredients is not critical, it is generally selected from 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food composition of the present invention.

The present invention also relates to a pharmaceutical composition for the prevention or treatment of inflammatory diseases containing acid colostrum milked by the Expela method as an active ingredient.

The pharmaceutical composition comprising the acidic colostrum according to the present invention is preferably a formulation of a cream, gel, patch, spray, ointment, warning, lotion, linen, pasta or cataplasma, but is not limited thereto.

A carrier, excipient or diluent, which may be included in the pharmaceutical composition including acid colostrum, may further include a pharmaceutically acceptable carrier, excipient or diluent in addition to the acid colostrum, and lactose, dextrose, sucrose, oligosaccharide, Sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydride Oxybenzoate, talc, magnesium stearate and mineral oil. When formulated, it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. which are commonly used.

Preferred dosages of the colostrum of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the pharmaceutical composition containing the acidic oil of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.

The present invention also relates to quasi-drugs for improving asthma or atopic dermatitis containing acid colostrum milked by the Expela method as an active ingredient.

The quasi-drug is prepared in any one formulation selected from solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsions, foundations, wax foundations and sprays. It is preferable, but it is not limited to this.

Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for explaining the present invention in more detail, it is obvious to those skilled in the art that the scope of the present invention is not limited by them.

실시예Example 1. One. in vitroin vitro 염증성 사이토카인의 발현량 변화 분석 Analysis of Changes in Inflammatory Cytokine Expression

Primary tracheal epithelial cells and A549 cells were treated with a sample of colostrum diluted 10-fold with DMSO to 0.01% (v / v) final, and after 1 hour, 50ng / ml of TNF-α and Stimulation was performed with 100 μg / ml of LPS for 11 hours. After 12 hours of treatment with acetic acid, cell lysates were obtained by lysis buffer, protein was quantified by Bradford method, and Western blot was performed to confirm changes in expression levels of proteins.

In the embodiment of the present invention, the three cultivars of crude, late and varieties of horticulture, inflammatory cytokines (IL-25, IL-33, against the samples for nine cases obtained through hydraulic compression or expeller milking) IL-5 and TSLP) expression level changes were analyzed.

[Test group]

Sample 1: crude species + hydraulic press (with 10% shell)

Sample 2: Crude + Hydraulic Press (no shell)

Sample 3: Crude + Expella Milking (without Shell)

Sample 4: live species + hydraulic press (with 10% shell)

Sample 5: All Species + Hydraulic Press (Skin Not Included)

Sample 6: All-breed + Expella Milking (without Shell)

Sample 7: vinegar + hydraulic press (with 10% shell)

Sample 8: Herbal + Hydraulic Press (no shell)

Sample 9: milkweed + xpella milking (no shell)

As a result, as shown in Figs. 1 to 4, when seeing the efficacy according to the method of extracting the colostrum in the A549 cells stimulated by LPS, in the analysis of the results of A549 cells stimulated by LPS in the analysis of the extruder than the hydraulic compression method At the time of milking, increased inflammatory cytokines (IL-25, IL-33, IL-5 and TSLP) expression was reduced in A549 cells stimulated by LPS, among which the efficacy of Hancho variety was remarkable.

In addition, based on the results in the A549 cells stimulated by the LPS, as a result of reconfirming the change in the expression level of inflammatory cytokines for Hancho variety in primary tracheal epithelial cells stimulated by LPS, It was confirmed that the expression level of increased cytokines in primary tracheal epithelial cells stimulated by LPS was reduced in the expeller milking samples.

실시예Example 2. 천식 마우스 모델에서의 2. Asthma in Mouse Model 산초유Sancho Milk 효능 확인 Efficacy Check

Based on the results of Example 1, the herbaceous cultivars milked with the Expel milking method of the present invention were orally administered to an OVA (ovalbumin) -induced asthma mouse model, and the number of inflammatory cells, expression of proteins involved in inflammation, and airway hypersensitivity. And histological analysis.

[Experimental animal]

Animals were purchased from Orientbio Inc. (Seongnam, Korea) for 6 week-old female mice of C57BL / 6 strain. To induce an asthma mouse model, 10 μg / mouse OVA (ovalbumin) and 1 mg of Alum were mixed in a total volume of 200 μl in saline, and sensitized by intraperitoneal administration on

days

0 and 14. After the first sensitization, 3% OVA (weight / volume) in saline was inhaled for 30 minutes using an ultrasonic nebulizer on the 21st, 22nd and 23rd days.

The raw colostrum was added corn oil (drug vehicle), and the crude colostrum was diluted to 0.2% and 2% of each sample. Corn oil and colostrum were orally administered 1 hour before the last 3% OVA challenge and 6 hours after the last 3% OVA challenge.

To confirm the efficacy of the colostrum, the mice were sacrificed at 48 hours after the last OVA challenge. The mouse model group was classified into the negative control group (SAL + VEH), the oVA group treated with ovalbumin, and the ovalbumin-treated and acid colostrum (0.2 or 2% per second) (FIG. 6).

(1)(One) 기관지 폐포 세척액(Bronchial alveolar lavage fluid ( BALBAL fluids)에서 염증 세포 분석 inflammatory cell analysis in fluids

Mice were sacrificed by cervical dislocation, 1 ml of PBS was added to the trachea to wash the lungs, and bronchial alveolar lavage fluid was obtained. Total cell number was measured using NucleoCounter (ChemoMetec, Allerod, Denmark), and BAL cell smears were prepared with cytospin (Thermo Eletronm Waltham, Mass.). For cell differentiation, after staining with Diff-Quik solution (Dade diagnostics of P.R. Inc.Aguada, Puerto Rico), 400 cells were counted and analyzed, and samples showing efficacy in inflammatory cell analysis were selected.

As a result, as shown in FIG. 7, the total cell number, inflammatory cells including eosinophil and lymphocytes were significantly increased in the asthma model, and the total cell number and eosinophil in the experimental group administered 2% per second. It was confirmed that the cell number of was reduced.

(2)(2) 웨스턴Weston 블랏Blot 및 밀도 분석(And density analysis ( densitometrydensitometry analysis) analysis)

Mouse lung tissue of the sample selected in the inflammatory cell analysis was homogenized with lysis buffer to obtain protein lysates of lung tissue. Proteins were quantified by the Bradford technique, followed by electrophoresis, membrane transfer, and blocking to incubate IL-4 and IL-13 antibodies overnight. The next day the blots were washed, the secondary antibodies reacted, the ECL reactions were analyzed and analyzed using the LAS instrument.

As a result, IL-4 and IL-13 proteins were increased in lung tissue of the asthma model. It was confirmed that the increased IL-4 and IL-13 protein was decreased in the animal model administered with the acetic acid of Hancho variety of the present invention (Fig. 8).

(3) 기도 저항성 측정 (3) airway resistance measurement

In order to evaluate the effect on the airway hypersensitivity of selected samples in inflammatory cell analysis, animal airway resistance meter Flexivent (Scientific Respiratory Equipment Inc., Montreal, Canada) was used. This was measured by airway resistance (Rrs) according to the change of methacholine concentration (0, 5, 10, 25, 50 mg / ㎖) in anesthesia of the mouse by the Invasive method. Mice were sprayed with 0.9% physiological saline for 10 seconds prior to inhaling methacholine to measure basal control airway hypersensitivity, and each mouse was treated with methacholine using an ultrasonic nebulizer to determine the difference in airway response to methacholine. It was measured while increasing the concentration of. After administration of each concentration of methacholine, the Rrs value was measured for 3 minutes and the average value was used. The change in airway function was expressed as a percentage based on the basal Rrs value obtained after 0.9% saline inhalation.

As a result of airway hypersensitivity analysis, asthma model group showed increased airway hypersensitivity in a dose-dependent manner compared to negative control group (SAL + VEH), and increased airway hypersensitivity was decreased in the experimental group administered 2% per second. It was confirmed (FIG. 9).

(4)(4) 조직학적 분석Histological analysis

For histological analysis of selected samples in inflammatory cell assay, lung tissue was removed from mice 48 hours after the last OVA challenge and fixed in 4% formalin. Samples were dehydrated and fixed with paraffin and attached to slides in 4 μm sections with a Leica model 2165 rotary microtome (Leica Microsystems Nussloch GmbH, Nussloch, Germany). The tissues were then deparaffinized and hydrolyzed and H & E stained. Histologically, the inflammatory scores were analyzed to evaluate lung inflammation.

As a result, the pathological examination of the asthma model showed a thickening of the epithelial cell layer, a significant increase in inflammatory cell infiltration around the bronchus and blood vessels, and significantly improved pathological changes in the experimental group treated with 2% per second. It could be observed (Fig. 10).

[통계 처리][Statistical processing]

All results are expressed as mean and standard error. In the statistical analysis, after the normality test, according to the normality test, scheffe's post-test was conducted by using one-way ANOVA, and p <0.05 was interpreted as statistically significant. If the test was not followed, the Kruskal-Wallis ANOVA test was followed by the Mann Whitney U test.

Claims

Health functional food composition for the prevention or improvement of inflammatory diseases containing acid colostrum milked by the Expela method as an active ingredient.
The health functional food composition for preventing or ameliorating an inflammatory disease according to claim 1, wherein the sancho oil is a sancho milk of Hancho variety.
The method of claim 1, wherein the inflammatory disease is asthma, bronchitis, chronic obstructive pulmonary disease, atopic dermatitis, allergy, systemic lupus erythematosus, scleroderma, ulcerative colitis, Crohn's disease, psoriasis, anaphylaxis, dermatitis, diabetic retinopathy, retinitis Macular degeneration, uveitis, conjunctivitis, arthritis, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, osteoporosis, diabetes, diabetic nephropathy, nephritis, nephritis, Sjogren's syndrome, Crohn's disease, autoimmune pancreatitis, periodontal disease, graft-versus-host disease, chronic Health functional food composition for the prevention or improvement of inflammatory diseases, characterized in that the pelvic inflammatory disease, endometritis, rhinitis, tonsillitis, otitis media, sore throat, cystitis and chronic prostatitis.
According to claim 1, wherein the composition is a health functional food composition for the prevention or improvement of inflammatory diseases, characterized in that the formulation is made of any one selected from powders, granules, pills, tablets, capsules, candy, syrups and beverages.
Pharmaceutical composition for the prevention or treatment of inflammatory diseases containing acid colostrum milked by the Expela method as an active ingredient.
A quasi-drug for improving asthma or atopic dermatitis, which contains acid colostrum milked by the Expela method as an active ingredient.
The method of claim 6, wherein the skin external preparation is in solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion, foundation, wax foundation, and spray A quasi-drug for improving asthma or atopic dermatitis, which is prepared by any one of the selected dosage forms.